AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22989819
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg) plus Hydrochlorothiazide (12.5 mg)
Trial: 20589313
Drug: ARC1779 (4-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARC1779 (4-5 microg/ml)
Trial: 20589313
Drug: ARC1779 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARC1779 and desmopressin combination
Trial: 17386345
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1 g) and Vitamin E (400 IU)
Trial: 9693397
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 0.02 mg ethinyl estradiol and 0.15 mg desogestrel (preparation A)
Trial: 9693397
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 0.03 mg ethinyl estradiol and 2.00 mg dienogest (preparation B)
Trial: 3277153
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of therapy with cefaclor (40 mg/kg/day)
Trial: 3277153
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of therapy with cefaclor (40 mg/kg/day)
Trial: 3277153
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days vs 10 days of therapy
Trial: 31210529
Drug: Ipragliflozin 50
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 50 mg/day
Trial: 30821047
Drug: Ipragliflozin 100
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 100 mg/day
Trial: 27495072
Drug: Bilateral ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound-guided split injection technique for rectus sheath block (RSB group, n=20)
Trial: 20650049
Drug: Test formulation:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation: escitalopram (10 mg tablet) manufactured by Apsen Farmacêutica S.A.
Trial: 20650049
Drug: Reference formulation:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation: escitalopram (Lexapro; 10 mg tablet) from Lundbeck Brasil Ltda
Trial: 16088856
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy for women with CMI
Trial: 16088856
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy for women without CMI
Trial: 1875542
Drug: 1% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% mepivacaine and buprenorphine 0.2 mg (48 ml.hr‐1)
Trial: 1875542
Drug: 1% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% mepivacaine and buprenorphine 0.4 mg (48 ml.hr‐1)
Trial: 1875542
Drug: saline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline and buprenorphine 0.2 mg (48 ml.hr‐1)
Trial: 1875542
Drug: saline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline and buprenorphine 0.4 mg (48 ml.hr‐1)
Trial: 6981522
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 g erythromycin ethyl succinate granules twice daily orally for 10 days)
Trial: 29195188
Drug: Individual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Cognitive Behavioral Therapy (ICBT)
Trial: 29195188
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioral Therapy (GCBT)
Trial: 24727078
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) combined (ICBT and GCBT)
Trial: 21901395
Drug: Adjuvant anthracycline-based
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant anthracycline-based dose-dense sequential chemotherapy
Trial: 21901395
Drug: Adjuvant anthracycline-based
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant anthracycline-based dose-dense sequential chemotherapy with paclitaxel
Trial: 20813593
Drug: Cefazedone 500
RxNorm normalized name: cefazedone
DrugBank: Cefazedone (DB13778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazedone 500 mg IV
Trial: 20813593
Drug: Cefazedone 1000
RxNorm normalized name: cefazedone
DrugBank: Cefazedone (DB13778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazedone 1000 mg IV
Trial: 20813593
Drug: Cefazedone 2000
RxNorm normalized name: cefazedone
DrugBank: Cefazedone (DB13778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazedone 2000 mg IV
Trial: 15923569
Drug: Carboxyaminoimidazole (CAI)
RxNorm normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxyaminoimidazole (CAI) 250 mg/d
Trial: 9809381
Drug: Creatine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (15 g/d)
Trial: 9809381
Drug: Creatine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (2 g/d)
Trial: 8430713
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 to 20 mg)
Trial: 8430713
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 to 100 mg)
Trial: 24944041
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg/day for 7 days) with PF-04449913 (200 mg single dose on day 4)
Trial: 24944041
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal with PF-04449913 (200 mg single dose)
Trial: 24944041
Drug: PF-04449913 alone
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 alone (200 mg single dose)
Trial: 22348605
Drug: Tapentadol 75
RxNorm normalized name: tapentadol 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol 75 mg t.d.s. for 48 h
Trial: 22348605
Drug: Oxycodone 5
RxNorm normalized name: oxycodone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5 mg t.d.s. for 48 h
Trial: 9106787
Drug: 20% fat
RxNorm normalized name: Intralipid 20% Fat Emulsion for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% fat emulsion formulation
Trial: 9106787
Drug: 2% formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% formulation enriched 10-fold with phospholipids
Trial: 3520619
Drug: Local antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local antibacterial agents (variety of local antibacterials)
Trial: 3520619
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent povidone-iodine (50 percent Betadine) solution
Trial: 30230266
Drug: Low-dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose treatment (150 M)
Trial: 30230266
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment (300 M)
Trial: 24462483
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg zinc sulfate for 14 days)
Trial: 15468574
Drug: Albendazole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (single dose)
Trial: 23147875
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy every 2 hours (CPAP 2 hrs)
Trial: 23147875
Drug: Incentive spirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive spirometry (IS) therapy
Trial: 23147875
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy every 4 hours (CPAP 4 hrs)
Trial: 19280112
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg once daily for 2 weeks
Trial: 19280112
Drug: Famotidine 10
RxNorm normalized name: famotidine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 10 mg twice daily for 2 weeks
Trial: 19280112
Drug: Famotidine 10
RxNorm normalized name: famotidine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 10 mg twice daily for a third 2-week period
Trial: 17192288
Drug: Tibolone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 1.25 mg/d
Trial: 17192288
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg/d
Trial: 17192288
Drug: CEE/MPA (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA (0.625 + 2.5 mg/d)
Trial: 10553738
Drug: Clozapine 100
RxNorm normalized name: clozapine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 100 mg/day
Trial: 10553738
Drug: Clozapine 300
RxNorm normalized name: clozapine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 300 mg/day
Trial: 15365707
Drug: Haloperidol 10
RxNorm normalized name: haloperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 10 mg/day (4-week trial)
Trial: 9700674
Drug: Cerebrolysin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (10 ml, 30 ml)
Trial: 9700674
Drug: Cerebrolysin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin 50 ml
Trial: 9700674
Drug: Cerebrolysin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (all doses)
Trial: 8305754
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of EMLA cream
Trial: 28265816
Drug: Morinidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morinidazole (500 mg twice daily for 14 days)
Trial: 28265816
Drug: Ornidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole (500 mg twice daily for 14 days)
Trial: 25540268
Drug: Inactivated whole‐virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated whole‐virus Vero cell culture‐derived RRV vaccine (2.5‐μg dose, Al(OH)(3)‐adjuvanted, with second and third doses after 3 weeks and 6 months)
Trial: 25540268
Drug: Inactivated whole‐virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated whole‐virus Vero cell culture‐derived RRV vaccine
Trial: 22957911
Drug: Platform-switched implant-abutment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switched implant-abutment connection (test)
Trial: 22957911
Drug: Platform-matched implant-abutment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-matched implant-abutment connection (control)
Trial: 16573800
Drug: Lansoprazole 60‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60‐mg intravenous bolus followed by 6‐mg/h continuous infusion
Trial: 16573800
Drug: Lansoprazole 90‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 90‐mg intravenous bolus followed by 6‐mg/h continuous infusion
Trial: 16573800
Drug: Lansoprazole 90‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 90‐mg intravenous bolus followed by 7.5‐mg/h continuous infusion
Trial: 16573800
Drug: Lansoprazole 90‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 90‐mg intravenous bolus followed by 9‐mg/h continuous infusion
Trial: 12452516
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metronidazole and povidone iodine
Trial: 10511022
Drug: Brinzolamide 1%
RxNorm normalized name: BRINZOLAMIDE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide 1% ophthalmic suspension
Trial: 10511022
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% ophthalmic solution
Trial: 2387667
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (200 mg twice daily for 4 weeks)
Trial: 6122232
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg propoxyphene napsylate (PN) in two divided doses
Trial: 6122232
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg methadone
Trial: 8498759
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg methadone
Trial: 25770879
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate gel (0.015% once daily for 3 days for face/scalp; 0.05% once daily for 2 days for trunk/extremities)
Trial: 22417254
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate gel
Trial: 25199059
Drug: Intravenous mepolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mepolizumab (75 mg every 4 weeks for 32 weeks)
Trial: 25199059
Drug: Subcutaneous mepolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous mepolizumab (100 mg every 4 weeks for 32 weeks)
Trial: 21114680
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (non-surgical periodontal therapy)
Trial: 20544030
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (control group)
Trial: 19526589
Drug: Interferon-alpha (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (3 million U subcutaneously 3x weekly, escalating to 18 MU)
Trial: 17511767
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg/day for 4 weeks increased to 120 mg/day for 8 weeks
Trial: 16493377
Drug: Hypocaloric balanced
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric balanced diet therapy with antioxidant and ω-3 supplementation
Trial: 16493377
Drug: Hypocaloric balanced
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric balanced diet therapy
Trial: 3610329
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) injection of 1 g cefpirome
Trial: 3610329
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection of 1 g cefpirome
Trial: 3610329
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) and Intramuscular (i.m.) injections of 1 g cefpirome
Trial: 25352437
Drug: 2RDA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2RDA (1.5 g·kg(‐1)·day(‐1))
Trial: 25352437
Drug: 1RDA (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1RDA (0.8 g·kg(‐1)·day(‐1))
Trial: 19342506
Drug: Pexacerfont 25
RxNorm normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexacerfont 25 mg qd
Trial: 19342506
Drug: Pexacerfont 100
RxNorm normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexacerfont 100 mg qd
Trial: 16478794
Drug: Etoposide-cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etoposide-cisplatin chemotherapy
Trial: 15270741
Drug: Family unit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family unit treatment (all infected family members treated)
Trial: 15270741
Drug: Index case
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index case treatment (index case only treated)
Trial: 10985630
Drug: Nickel sulfate
RxNorm normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel sulfate patch tests at 1, 3, and 7 cm distance from potassium dichromate patches
Trial: 10985630
Drug: Nickel sulfate
RxNorm normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel sulfate patch tests at 1 cm distance from potassium dichromate patches
Trial: 10985630
Drug: Nickel sulfate
RxNorm normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel sulfate patch tests
Trial: 7510736
Drug: L-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (3 mg/kg)
Trial: 8364286
Drug: Antimicrobial drugs
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial drugs (AMDs) prescribed to hospitalized children
Trial: 3511372
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide plus low-dose prednisone
Trial: 3511372
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral prednisone alone
Trial: 1412641
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg/kg body weight)
Trial: 3293827
Drug: Amodiaquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (25 mg/kg)
Trial: 3293827
Drug: Sulfadoxine‐pyrimethamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (25 mg/kg and 1.25 mg/kg)
Trial: 3293827
Drug: Amodiaquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (25 mg/kg) + sulfadoxine‐pyrimethamine (25 mg/kg and 1.25 mg/kg)
Trial: 25138579
Drug: Tamsulosin OCAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin OCAS 0.4 mg and desmopressin MELT 60 mcg (D/T group)
Trial: 25138579
Drug: Tamsulosin OCAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin OCAS 0.4 mg only (T group)
Trial: 22802301
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (with antidepressants)
Trial: 21791883
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VerifyNow P2Y12 (PRU) and Aspirin (ARU) testing
Trial: 17361920
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg/day orally
Trial: 17361920
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal therapy (bicalutamide)
Trial: 2877131
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone substitution therapy (TTS)
Trial: 29178769
Drug: Desensitizing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing agents (five commercially available agents applied according to manufacturers' instructions)
Trial: 29178769
Drug: Desensitizing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing agents (five commercially available agents)
Trial: 25100892
Drug: Caffeine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.5 mg/kg)
Trial: 25100892
Drug: Maltodextrin (CHO)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (CHO) (1 g/kg)
Trial: 22888676
Drug: Probiotic cheese
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic cheese comprising L. plantarum TENSIA (DSM 21380) consumed for 3 weeks
Trial: 22888676
Drug: Probiotic cheese
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic cheese comprising L. plantarum TENSIA (DSM 21380)
Trial: 10534516
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) therapy, 3 x 10(6) U s.c., three times a week (post-HD)
Trial: 2270581
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg OTC three times/day
Trial: 19883809
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin (group A)
Trial: 11477461
Drug: High group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High group (500 g/day fruit and vegetables and 200 ml/day fruit juice)
Trial: 11477461
Drug: Low group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low group (100 g/day fruit and vegetables)
Trial: 8206395
Drug: Octreotide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (single injection)
Trial: 31563344
Drug: Ceftolozane-tazobactam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane-tazobactam (3 g intravenously every 8 h for 8-14 days)
Trial: 31563344
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g intravenously every 8 h for 8-14 days)
Trial: 23660721
Drug: Distributed training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distributed training group with five monthly unsupervised training sessions of 30 min on a box trainer (group 3)